Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2016;57(3):728-30.
doi: 10.3109/10428194.2015.1076930. Epub 2015 Oct 5.

A phase I study of carfilzomib for relapsed or refractory acute myeloid and acute lymphoblastic leukemia

Lukas D Wartman  1 , Mark A Fiala  1 , Theresa Fletcher  1 , Emily R Hawkins  1 , Amanda Cashen  1 , John F DiPersio  1 , Meagan A Jacoby  1 , Keith E Stockerl-Goldstein  1 , Iskra Pusic  1 , Geoffrey L Uy  1 , Peter Westervelt  1 , Ravi Vij  1
Affiliations
Clinical Trial

A phase I study of carfilzomib for relapsed or refractory acute myeloid and acute lymphoblastic leukemia

Lukas D Wartman et al. Leuk Lymphoma. 2016.
No abstract available

PubMed Disclaimer

References

    1. McBride A, Ryan PY. Proteasome inhibitors in the treatment of multiple myeloma. Expert Rev Anticancer Ther. 2013;13(3):339–358. - PubMed
    1. Niewerth D, Dingjan I, Cloos J, Jansen G, Kaspers G. Proteasome inhibitors in acute leukemia. Expert Rev Anticancer Ther. 2013;13(3):327–337. - PubMed
    1. Horton TM, Pati D, Plon SE, et al. A phase 1 study of the proteasome inhibitor bortezomib in pediatric patients with refractory leukemia: a Children's Oncology Group study. Clin Cancer Res. 2007;13(5):1516–1522. - PubMed
    1. Attar EC, De Angelo DJ, Supko JG, et al. Phase I and pharmacokinetic study of bortezomib in combination with idarubicin and cytarabine in patients with acute myelogenous leukemia. Clin Cancer Res. 2008;14(5):1446–1454. - PubMed
    1. Messinger Y, Gaynon P, Raetz E, et al. Phase I study of bortezomib combined with chemotherapy in children with relapsed childhood acute lymphoblastic leukemia (ALL): a report from the therapeutic advances in childhood leukemia (TACL) consortium. Pediatr Blood Cancer. 2010;55(2):254–259. - PubMed

MeSH terms

LinkOut - more resources